Makes cardiac ablation products for atrial fibrillation treatment.
Jun 2026Revenue $570M/yrExpenses $557M/yr
No trend
Figures by year
Is AtriCure profitable?
Yes. In the 12 months to Jun 2026, revenue was $570M and expenses $557M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $535M | $544M | −$9.45M |
| Dec 2024 | $465M | $505M | −$40.0M |
| Dec 2023 | $399M | $426M | −$26.7M |
| Dec 2022 | $330M | $373M | −$42.7M |
| Dec 2021 | $274M | $219M | $55.2M |
| Dec 2020 | $207M | $251M | −$44.2M |
| Dec 2019 | $231M | $264M | −$33.1M |
| Dec 2018 | $202M | $219M | −$17.1M |
| Dec 2017 | $175M | $200M | −$25.0M |
| Dec 2016 | $155M | $186M | −$31.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.